Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe

November 16th 2023

By Skylar Jeremias

In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.

Part 2: French Study Finds Trastuzumab Biosimilar Program Could Generate Meaningful Savings

November 15th 2023

By Skylar Jeremias

In part 2 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® explores a cost-effectiveness analysis evaluating the use of subcutaneous trastuzumab biosimilars to treat breast cancer in a French hospital setting.

Switching Patients from Reference Product to Biosimilar

November 14th 2023

Insight surrounding the switch from reference drugs to biosimilars is provided by Bincy Abraham, MD, MS.

Initiating Biosimilar Treatment in Patients Without Previous Reference Biologic Experience

November 14th 2023

Vibeke Strand, MD, evaluates implementation of biosimilars in patients with no history of reference biologic use.

Part 1: Oncology Biosimilars Offer Comparable Benefits to Originators at Lower Prices

November 14th 2023

By Skylar Jeremias

In part 1 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® looks at a retrospective study comparing the clinical benefits, price changes, and uptake associated with oncology biosimilars in China.

Panelists Deliberate Strategies to Enhance Biosimilar Integration in Managed Care Spaces

November 13th 2023

By Skylar Jeremias

At the recent Academy of Managed Care Pharmacy Nexus meeting, panelists discussed the impact of introducing biosimilars in new medical fields, emphasizing the need for more education and collaboration to ensure their smooth integration into health care systems.

Dr Ryan Haumschild Draws Link Between Biosimilars, Health Equity in Breast Cancer

November 12th 2023

By Skylar Jeremias

Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, discusses the growth and continued challenges facing biosimilars used to treat breast cancer.

Public Payer in Poland Saves €243 Million by Using Biosimilar TNF Inhibitors

November 11th 2023

By Skylar Jeremias

The use of biosimilars of tumor necrosis factor (TNF) inhibitors within Poland’s public payer saved over €243 million from 2013 to 2021, with about 68% of that coming from the rheumatic musculoskeletal diseases alone.

The Top 5 Biosimilar Articles for the Week of November 6

November 10th 2023

By The Center for Biosimilars Staff

Here are the top 5 biosimilar articles for the week of November 6, 2023.

Real-World Data Confirm Safety, Efficacy of CT-P13 in Inflammatory Diseases

November 9th 2023

By Skylar Jeremias

A real-world analysis from Japan confirmed that CT-P13, an intravenous infliximab biosimilar, had comparable safety and efficacy to the reference product (Remicade; infliximab) in patients with immune-mediated inflammatory diseases.